Lilly presents Phase 3b Taltz (ixekizumab) plus Zepbound (tirzepatide) data at AAD Annual Meeting

Novartis to acquire Excellergy in USD2bn deal

Almirall reports lebrikizumab demonstrated sustained long-term control in atopic dermatitis through four years

AstraZeneca's tozorakimab meets primary endpoints in two Phase III COPD trials

Pharming receives positive CHMP opinion for Joenja marketing authorisation

Biocytogen partner NEOK Bio secures FDA IND clearance for cancer therapy candidate

Hoth Therapeutics deploys OpenClaw AI platform for drug discovery

Insilico Medicine and Tenacia expand AI-driven R&D collaboration

Eisai and Nuvation Bio report taletrectinib MAA validated by European regulator

Novo Nordisk's Awiqli once-weekly basal insulin treatment approved by US FDA

Kodiak Sciences reports positive Phase 3 results for Zenkuda in diabetic retinopathy

Iterion Therapeutics reports first patient dosed in phase 1/2 trial of tegavivint in colorectal cancer

SciTech Development reports early-stage clinical data from Phase 1a trial of ST-001 nanoFenretinide at USCLC Annual Workshop 2026

Clarity Pharmaceuticals signs copper-64 manufacturing agreement with Theragenics

Merck to acquire Terns Pharmaceuticals for USD6.7bn